A citation-based method for searching scientific literature

Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman, Hossein Borghaei, Suresh S Ramalingam, Julie Brahmer, Martin Reck, Kenneth J O'Byrne, William J Geese, George Green, Han Chang, Joseph Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith Nathan, Luis Paz-Ares. N Engl J Med 2018
Times Cited: 1394



Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny, Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D Hellmann, Omid Hamid, Jonathan W Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Z Rutledge, Jin Zhang, Jared K Lunceford, Reshma Rangwala, Gregory M Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi. N Engl J Med 2015
Times Cited: 3393




List of shared articles



Times cited

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms.
Mu-Yang Huang, Xiao-Ming Jiang, Bing-Lin Wang, Yang Sun, Jin-Jian Lu. Pharmacol Ther 2021
3


Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab.
Kengo Kuriyama, Takehiko Yokobori, Makoto Sohda, Nobuhiro Nakazawa, Toshiki Yajima, Ichiro Naruse, Hiroyuki Kuwano, Ken Shirabe, Kyoichi Kaira, Hiroshi Saeki. Oncol Lett 2021
1

Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
Åsa Kristina Öjlert, Daniel Nebdal, Marius Lund-Iversen, Renée Åstrøm Ellefsen, Odd Terje Brustugun, Jon Michael Gran, Ann Rita Halvorsen, Åslaug Helland. Acta Oncol 2021
0


Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles.
Bo Ling, Guangbin Ye, Qiuhua Zhao, Yan Jiang, Lingling Liang, Qianli Tang. Front Mol Biosci 2021
0

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Alessio Cortellini, Andrea De Giglio, Katia Cannita, Diego L Cortinovis, Robin Cornelissen, Cinzia Baldessari, Raffaele Giusti, Ettore D'Argento, Francesco Grossi, Matteo Santoni,[...]. Thorac Cancer 2021
6

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem,[...]. Oncoimmunology 2021
1

Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
Lianghao Zhang, Longqing Li, Yonghao Zhan, Jiange Wang, Zhaowei Zhu, Xuepei Zhang. Front Oncol 2021
2

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina, Delvys Rodriguez-Abreu, Joaquín Casal-Rubio, Teresa Moran Bueno, Reyes Bernabé-Caro, Diego Pérez Parente, Pedro Ruiz-Gracia,[...]. J Clin Med 2021
0

Predictive biomarkers for response to immune checkpoint inhibition.
Benjamin Shum, James Larkin, Samra Turajlic. Semin Cancer Biol 2021
2

Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Maximilian Boesch, Florent Baty, Sacha I Rothschild, Michael Tamm, Markus Joerger, Martin Früh, Martin H Brutsche. Br J Cancer 2021
0


Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Roberto Ferrara, Martina Imbimbo, Reem Malouf, Sophie Paget-Bailly, François Calais, Corynne Marchal, Virginie Westeel. Cochrane Database Syst Rev 2021
0

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui,[...]. Front Oncol 2021
0

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
Hao Wang, Shanhao Chen, Die Meng, Chunyan Wu, Junjie Zhu, Minlin Jiang, Jing Ning, Shengyu Wu, Lijia Wu, Jingjie Li,[...]. Onco Targets Ther 2021
0

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.
Tao Ouyang, Yanyan Cao, Xuefeng Kan, Lei Chen, Yanqiao Ren, Tao Sun, Liangliang Yan, Bin Xiong, Bin Liang, Chuansheng Zheng. Front Oncol 2021
0

Advancing to the era of cancer immunotherapy.
Yun Wang, Min Wang, Hao-Xiang Wu, Rui-Hua Xu. Cancer Commun (Lond) 2021
0

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg. Nat Rev Clin Oncol 2021
1

TMB in NSCLC: A Broken Dream?
Sara Bravaccini, Giuseppe Bronte, Paola Ulivi. Int J Mol Sci 2021
0